Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
about
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsInflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation.Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.Calcineurin inhibitors and rapamycin: cancer protection or promotion?Update of the management of chronic psoriasis: new approaches and emerging treatment options.Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.Therapeutic potential of macrolide immunosuppressants in dermatology.Formulation Development and Toxicity Assessment of Triacetin Mediated Nanoemulsions as Novel Delivery Systems for RapamycinGerman evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.Novel pharmacological approaches in the treatment of psoriasis.Emerging drugs in psoriasis.The use of ciclosporin in psoriasis.Basic immunosuppressive drugs outside solid organ transplantation.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Severe psoriasis treated with a new macrolide: everolimus.Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized studyActivation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.mTOR inhibitor-associated dermatologic and mucosal problems.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.Current and emerging systemic treatment strategies for psoriasis.Combination therapy in psoriasis: an evidence-based review.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.Safety of mTOR inhibitors in adult solid organ transplantation.Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibitionmTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target.Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.Severe atopic dermatitis treated with everolimus.[New immunosuppressive agents for treating psoriasis].[Development and pre-clinical aspects of pimecrolimus].Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.German S3-guidelines on the treatment of psoriasis vulgaris (short version).
P2860
Q26823023-3B111D9B-5688-4986-9B43-A0A478FB3E9DQ33897776-66F19076-90B2-42C8-BC95-A2ECCC7381D3Q34327203-37DB3E8F-F553-4C02-90DF-3AE2E7C9183CQ34578721-7AEA2011-6C54-42E3-B577-58E840606606Q34620375-BB4AD615-45FF-4D50-93A3-34AF119EC5F1Q35015840-52459D1E-D156-4D4F-93B9-CA69881E5F41Q35680649-BE7E5068-3C6A-4DBE-A17F-083D8FDA0DB7Q35843283-08744067-6E77-4901-90F7-376577513324Q35875481-618991BB-5495-450B-8798-3D0849AE7F98Q35922976-1C5E2F98-EB87-4895-9487-F635359BE48FQ36008673-30990805-125C-4A15-888B-B671A9AD6F16Q36179686-A690CA77-9D50-4C8D-8FE6-3B358871AA22Q36374570-1297734C-3664-49EA-BDAF-CD219077E5BAQ36407314-064F3EC4-79AA-4D0C-8AD7-68E2B8941B8AQ36574341-92955F11-1208-4638-BFB7-F5C81487BBFDQ36708370-3947E2CB-9DC8-489A-8E2B-F7AECA0590AFQ37112911-5DD8510B-2E80-4CD8-9BAB-3886AD305E60Q37649641-8C695766-6C4B-479C-811A-11CD7AA62ED3Q37710669-AD463403-4CF9-480A-955C-0FDACA839585Q37873950-EEB9212A-5CC0-42F8-A4F9-27628B41B93DQ37918698-413A3CD2-3F4C-48E5-B3F0-9CD2AE17FEA8Q38039491-DE32D949-D765-49C3-B1B9-9072AC0F09A6Q38074846-D06537F9-0F85-42DE-95D2-AF1782BEC96AQ38084325-C76C4278-8E1C-418F-9325-A20CFD23085FQ38223953-3E81A3A1-263F-4F27-89FA-5C1327B37249Q38669190-5C045CB1-B94A-4650-A9B8-0165B70BF845Q38841006-AD504C86-C036-46E5-938A-D268B4364A8EQ38914374-ADA0A959-9CD8-409D-B174-AAA207356662Q39034577-5BF4BE82-3FB6-4C4E-ABC5-35771C13F4AEQ41858959-C7A4E4E6-D158-4D89-AD6A-F9916070920FQ41884115-C8AA1A9C-C283-4EB2-B391-AA24C06561D3Q42520536-4FA4C031-30C3-4816-901E-05272A34EC75Q42680562-01C31C93-8593-4B32-A6D0-14C40A13D9F9Q43232058-A044C7AA-F6CD-4EFD-AD0C-12D74E309935Q44360566-4EB79BEA-8EC4-42A7-8828-1D08C6697D1FQ44420839-4D4CC483-ACA7-4A26-9810-EB47D9789B16Q46445406-635C747E-F7F9-4830-8857-D52984209F69Q46646002-CF05BA42-5F55-47BF-8149-0DAFD802F74EQ47260366-36D580D2-4136-455E-8D68-A096513EC7D6Q48480123-341790EE-6256-4047-A486-901B40412877
P2860
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@ast
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@en
Efficacy of sirolimus
@nl
type
label
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@ast
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@en
Efficacy of sirolimus
@nl
prefLabel
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@ast
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@en
Efficacy of sirolimus
@nl
P2093
P2860
P1476
Efficacy of sirolimus (rapamyc ...... a randomized controlled trial.
@en
P2093
B Sassolas
Sirolimus European Psoriasis Study Group
P2860
P304
P356
10.1046/J.1365-2133.2001.04376.X
P407
P577
2001-09-01T00:00:00Z